Page 25 - Ace2 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

South Africa SARS-CoV-2 variant B.1.351 easily escapes Sputnik vaccine The current pandemic of novel coronavirus disease 2019 (COVID-19) was caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has undergone numerous mutations in its genome to emerge as different variants. As of now, a dozen vaccines have received emergency use authorization, and many countries around the world have initiated mass vaccination campaigns. A new preprint research paper posted to the medRxiv* server reports on vaccine resistance data that pushes the end of the pandemic further away. ...

CAL20.C SARS-CoV-2 variant skyrocketing in California evades host immune response The effect of different neutralizing antibodies, both vaccine-elicited and from convalescent sera, suggests new variants are emerging that can evade the human immune response. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to host cells via its spike protein, which has two parts, the S1 and S2 subunits. The S1 subunit has the receptor-binding domain (RBD) and the N-terminal domain (NTD). The RBD binds to the host angiotensin-converting enzyme 2 (ACE2) to infect host cells. Neutralizing an...

New nanoparticle SARS-CoV-2 vaccine confers robust protection with single dose after two weeks In a methodologically ‘state-of-the-art’ approach, US researchers have developed a protein-based nanoparticle vaccine against coronavirus disease (COVID-19), with a swift generation of antibodies and the potential to protect individuals who cannot receive other COVID-19 vaccines for medical reasons. The research is posted to the bioRxiv* preprint server. Vaccines currently in use against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a causative agent of COVID-19, focus on th...

The use of mammalian cell surface display for rapid characterization of SARS-CoV-2 variants A research group from the U.S. demonstrated the practicality of a spike display system in order to accelerate vaccine design, but also to swiftly appraise the effects of mutations in emerging strains of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Their results are currently available on the bioRxiv* preprint server. SARS-CoV-2, the causative agent of the ongoing coronavirus disease (COVID-19), uses its spike glycoprotein to interact with angiotensin-converting enzyme 2 (ACE2) in ...

Antibodies produced from infection with SARS-CoV-2 501Y.V2 protect against other variants As the coronavirus disease 2019 (COVID-19) pandemic continues to claim thousands of lives daily around the world, the pathogen responsible for it, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to undergo mutational changes. A recent paper in the journal Nature shows that while earlier lineages do not elicit antibodies capable of efficiently neutralizing the newly emerged South African variant, SARS-CoV-2 501Y.V2 (B.1.351), the converse does occur. The SARS-CoV-2 501Y.V2 var...